Hudson Bay Capital Management’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Hudson Bay Capital Management’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-54,836	Closed	-$1.04K	–	1090
2023 Q1	$1.04K	Hold	54,836	–	–	﹤0.01%	839
2022 Q4	$8.16K	Hold	54,836	–	–	﹤0.01%	877
2022 Q3	$9K	Hold	54,836	–	–	﹤0.01%	1131
2022 Q2	$7K	Hold	54,836	–	–	﹤0.01%	1274
2022 Q1	$43K	Hold	54,836	–	–	﹤0.01%	1028
2021 Q4	$33K	Hold	54,836	–	–	﹤0.01%	1028
2021 Q3	$52K	Hold	54,836	–	–	﹤0.01%	930
2021 Q2	$77K	Buy	+54,836	New	+$47.9K	﹤0.01%	891

Other funds holding PEARW

Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Hudson Bay Capital Management's PEARW Position: Q2 2023 in Review

Hudson Bay Capital Management sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2023, closing a stake of 54,836 shares — an estimated $1.04K sold.

Hudson Bay Capital Management first reported a position in PEARW in Q2 2021 and held it in 8 quarters. The position peaked at $77K in Q2 2021. 2 funds tracked by Wall St. Rank hold PEARW as of Q2 2023.

Hudson Bay Capital Management reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2023 after selling out during the quarter.
Hudson Bay Capital Management sold 54,836 Pear Therapeutics, Inc. Warrant shares in Q2 2023, an estimated $1.04K.
Hudson Bay Capital Management first reported a position in Pear Therapeutics, Inc. Warrant in Q2 2021 and held it in 8 quarters.
Hudson Bay Capital Management's Pear Therapeutics, Inc. Warrant position peaked at $77K in Q2 2021.
2 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2023.

Based on Hudson Bay Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.